Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Waldenstrom's Macroglobulinemia
NCT00005609Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Apr 2000
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of rituximab in Waldenström macroglobulinemia (WM), sponsored by Eastern Cooperative Oncology Group. Started Apr 2000; status: completed.
02
Drugs
rituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00005609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005609.